SML4175
TH-Z145
≥90% (HPLC)
Synonym(s):
(2-(3-(Octyloxy)phenyl)ethane-1,1-diyl)bis(phosphonic acid), P,P′-[2-[3-(Octyloxy)phenyl]ethylidene]bis[phosphonic acid]
Sign Into View Organizational & Contract Pricing
About This Item
Empirical Formula (Hill Notation):
C16H28O7P2
CAS Number:
Molecular Weight:
394.34
MDL number:
Quality Level
Assay
≥90% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
O=P(O)(C(P(O)(O)=O)CC1=CC(OCCCCCCCC)=CC=C1)O
Biochem/physiol Actions
Potent and selective mevalonate (MVA) pathway geranylgeranyl diphosphate synthase (GGPPS) inhibitor that stimulates immune responses in vivo.
TH-Z145 is a potent and selective geranylgeranyl diphosphate synthase (GGPPS) inhibitor (IC50 = 210 nM; FPPS IC50 >30 µM) that stimulates immune responses by blocking the mevalonate (MVA) pathway-mediated post-translational protein geranylgeranylation. When co-administered with antigen in mice in vivo, TH-Z145 triggers strong adjuvant responses, increasing OVA-specific antibody titres (in mice immunized with 100 μg OVA + 100 μg TH-Z145) and protects against death caused by live influenza virus PR8 challenge (in mice immunized with 5 μg PR8 HA1 subunit containing TH-Z145). TH-Z145 adjuvant efficacy is blocked by GGPP and synergized with HMG-CoA inhibitor simvastatin.
TH-Z145 is a potent and selective geranylgeranyl diphosphate synthase (GGPPS) inhibitor (IC50 = 210 nM; FPPS IC50 >30 µM) that stimulates immune responses by blocking the mevalonate (MVA) pathway-mediated post-translational protein geranylgeranylation. When co-administered with antigen in mice in vivo, TH-Z145 triggers strong adjuvant responses, increasing OVA-specific antibody titres (in mice immunized with 100 μg OVA + 100 μg TH-Z145) and protects against death caused by live influenza virus PR8 challenge (in mice immunized with 5 μg PR8 HA1 subunit containing TH-Z145). TH-Z145 adjuvant efficacy is blocked by GGPP and synergized with HMG-CoA inhibitor simvastatin.
Regulatory Information
新产品
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Chenchen Guo et al.
Nature cancer, 3(5), 614-628 (2022-04-23)
Small cell lung cancer (SCLC) lacks effective treatments to overcome chemoresistance. Here we established multiple human chemoresistant xenograft models through long-term intermittent chemotherapy, mimicking clinically relevant therapeutic settings. We show that chemoresistant SCLC undergoes metabolic reprogramming relying on the mevalonate
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
Dennis Juarez et al.
Cancer research communications, 3(12), 2497-2509 (2023-11-13)
The BCL2 inhibitor venetoclax promotes apoptosis in blood cancer cells and is approved for treatment of chronic lymphocytic leukemia and acute myeloid leukemia. However, multiple myeloma cells are frequently more dependent on MCL-1 for survival, conferring resistance to venetoclax. Here
Yun Xia et al.
Cell, 175(4), 1059-1073 (2018-10-03)
Motivated by the clinical observation that interruption of the mevalonate pathway stimulates immune responses, we hypothesized that this pathway may function as a druggable target for vaccine adjuvant discovery. We found that lipophilic statin drugs and rationally designed bisphosphonates that
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service